A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
Sponsor
Hoffmann-La Roche (Industry)
Overall Status
Completed
CT.gov ID
NCT00002367
Collaborator
(none)
40
2
20
Study Details
Study Description
Brief Summary
To evaluate the efficacy of Saquinavir-SGC combination with Zidovudine and Lamivudine in the treatment of HIV-1 infected patients with no previous anti-retroviral drug therapy.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Detailed Description
All enrolled patients will receive the following 3 drug combination: Saquinavir, Zidovudine and Lamivudine. Efficacy and duration of anti-viral response will be evaluated by monitoring of HIV-1 RNA levels. Patients below the detectable limit of 200 copies/ml will be analyzed using the Ultra-direct method with a detection limit of 20 copies/ml. CD4 and CD8 cell counts will also be analyzed.
Study Design
Study Type:
Interventional
Intervention Model:
Parallel Assignment
Primary Purpose:
Treatment
Official Title:
An Open-Label, Non-Comparative Study of Saquinavir-SGC in Combination With Zidovudine (AZT) and Lamivudine (3TC) in the Treatment of HIV-1 Infected Patients With No Previous Anti-Retroviral Drug Therapy
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
16 Years
to 0 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria
Patients must have:
-
Plasma HIV-1 RNA titers > 10,000 copies/ml.
-
CD4 cell count > 100 cells/mm3.
Exclusion Criteria
Co-existing Condition:
Patients with any of the following conditions will be excluded:
- Any prior anti-retroviral drug therapy.
Prior Medication:
Excluded:
Previous anti-retroviral drug therapy.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | AIDS Healthcare Foundation Labs | Los Angeles | California | United States | 90048 |
2 | Urgent Care Ctr / North Broward Hosp District | Fort Lauderdale | Florida | United States | 33316 |
Sponsors and Collaborators
- Hoffmann-La Roche
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00002367
Other Study ID Numbers:
- 229F
- NR15503
- M61005
First Posted:
Aug 31, 2001
Last Update Posted:
Jun 24, 2005
Last Verified:
Aug 1, 1997
Keywords provided by ,
,
Additional relevant MeSH terms: